This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Aug 16, 2024
•
9 min read
Medicare reveals first drug price negotiations, Bavarian Nordic stock nearly doubles on mpox global health emergency concerns, Zealand Pharma searches for commercial partner for their obesity med, Abata (Treg) lands strategic investment from BMS, Bayer's restructuring (allegedly) ain't slowing down BD efforts, SIGA Tpoxx antiviral misses primary endpoint, the L's keep stacking for Lykos as they cut 75% of their staff
Aug 15, 2024
Gilead snags accelerated approval for cholangitis med, Acelyrin posts positive Ph3 skin disorder data, Avidity's up to $300M public offering, Arrowhead wants to get in on obesity, Avenge Bio and Galera Therapeutics wind down, bluebird bio stocks sinks as sickle-cell gene therapy uptake moves at glacial pace, Grail and Evotec slash a combined 750 jobs, WHO declares mpox a public health emergency
Aug 14, 2024
Eli Lilly opens glassy $700M Boston R&D site, Evotec handed $75M milestone from BMS, atai Life Science and Cybin want to succeed where Lykos has stumbled, Novartis heart failure generic suit fails (again), Actuate Therapeutics' underwhelming IPO, Prolific Machines nabs grant to biomanufacture mAbs for low- and middle-income countries, and Boundless Bio doesn't have boundless job openings
Aug 13, 2024
8 min read
J&J's talc lawsuit saga may be ending, Sandoz biosimilar approval signals fourth Eylea (Regenron) competitor, Pfizer lands immunocompromised RSV Ph3 win, Halda Therapeutics $126M Series B, $924M botox industry M&A, FibroGen to layoff 127 SF-based staffers, and there's a new "largest protein" in town
Aug 12, 2024
ARS Pharmaceuticals nasal epinephrine spray FDA approved, Merck pays up to $1.3B for bispecific asset, Avidity posts positive Ph1/2 DMD data, Sandoz's Humira biosimilar keeps on making money, Cabaletta reports adverse event in CAR-T lupus trial, 23andMe tries to cash in on GLP-1 hype, and Lykos Therapeutics can't catch a break with 3 of their papers getting redacted
Aug 9, 2024
10 min read
Eli Lilly's stupendous Q2 results, AI-biotechs Recursion & Exscientia merge, Vertex's Casgevy reaches reimbursement deal with UK's NHS, Novartis' FDA accelerated approval for nephropathy med, Bavarian Nordic snag $150M+ BARDA contract, Sanofi's Ph3 myeloma win, Merck & Co.'s Ph3 lung cancer miss, and Sarepta's earnings disappoint investors
Aug 8, 2024
Novo Nordisk posts disappointing Q2 earnings, Chugai acquires Japan rights to Roche IBD med, Amgen's Horizon acquisition continues to pay off in Q2 earnings, IDRx's $120M Series B, Pharmacosmos buys G1 Therapeutics, Novo pulls back Wegovy heart failure submission, and insider trading doesn't pay
Aug 7, 2024
11 min read
Agios to collect a fat $1.1B milestone payment after FDA approval, Symbiotic Capital life science credit firm launches with $600M, Shinobi Therapeutics extends Series A + lands $59M grant, Pfizer invests in antimicrobial resistance, Merck & Co. signs T-cell engager bispecific partnership with Daiichi Sankyo, Bayer touts massive management cuts over H1 2024, BioMarin shrinks Roctavian gene therapy ambitions
Aug 6, 2024
6 min read
Bayer posts heart failure Ph3 win, Mallinckrodt sells Therakos division to PE firm at a substantial loss, MBX Biosciences $63.5M Series C, Actinium turns to partnership after FDA rejection, BioNTech posts $883M net loss for Q2, and gene therapy biotech Lacerta Therapeutics shuts down
Aug 5, 2024
Vir in-licences three Sanofi T-cell engager clinical assets, Paragon Therapeutic's fourth opco launches with $80M, Vertex boosts 2024 outlook on Casgevy sales (and also cuts two rare disease Ph1 assets), Eli Lilly's Zepbound, Mounjaro no longer on US shortage list, Ribon Therapeutics shutters
Aug 2, 2024
Gene therapy legend James Wilson launches two new companies, Adaptimmune's engineered cell therapy for solid tumors gets historic accelerated approval, venBio closes fifth life science fun at $500M+, Sanofi commits $1.4B for new insulin manufacturing facility, uniQure decimates its workforce via 65% layoffs, and Novartis continues to fight FDA's Entresto generic approval
Aug 1, 2024
J&J lands FDA approval for "foundational" multiple myeloma combo, Eisai drops more Leqembi data in support of long term use, Umoja cleared to dose first patients with their in situ CAR-T, AIRNA raises $60M Series A, Sanofi sues Sarepta over their DMD gene therapy, and EuroAPI is having a tough "transition year"
